Heron Therapeutics Inc (NASDAQ:HRTX) Given Average Rating of “Hold” by Analysts

Share on StockTwits

Shares of Heron Therapeutics Inc (NASDAQ:HRTX) have been assigned an average rating of “Hold” from the nine analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $58.00.

A number of equities research analysts have issued reports on the stock. ValuEngine upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. BidaskClub upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 10th. Evercore ISI restated a “buy” rating and set a $75.00 price target on shares of Heron Therapeutics in a report on Tuesday, August 13th. Northland Securities restated a “buy” rating and set a $55.00 price target on shares of Heron Therapeutics in a report on Monday, August 5th. Finally, Stifel Nicolaus restated a “buy” rating and set a $38.00 price target on shares of Heron Therapeutics in a report on Monday, August 5th.

Heron Therapeutics stock traded down $0.25 during midday trading on Thursday, reaching $20.49. The stock had a trading volume of 7,560 shares, compared to its average volume of 947,795. Heron Therapeutics has a twelve month low of $15.68 and a twelve month high of $37.25. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.01 and a quick ratio of 3.70. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of -8.38 and a beta of 1.47. The firm’s fifty day simple moving average is $17.75 and its two-hundred day simple moving average is $20.27.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Monday, August 5th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.02. Heron Therapeutics had a negative net margin of 172.07% and a negative return on equity of 56.89%. The company had revenue of $36.66 million during the quarter, compared to the consensus estimate of $31.04 million. As a group, sell-side analysts predict that Heron Therapeutics will post -2.73 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in HRTX. Clearbridge Investments LLC raised its holdings in shares of Heron Therapeutics by 153.4% during the 1st quarter. Clearbridge Investments LLC now owns 2,180,577 shares of the biotechnology company’s stock valued at $53,293,000 after purchasing an additional 1,320,025 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Heron Therapeutics by 319.0% during the 1st quarter. JPMorgan Chase & Co. now owns 889,696 shares of the biotechnology company’s stock valued at $21,744,000 after purchasing an additional 677,354 shares in the last quarter. WS Management Lllp bought a new position in shares of Heron Therapeutics during the 1st quarter valued at $11,174,000. C WorldWide Group Holding A S raised its holdings in shares of Heron Therapeutics by 178.5% during the 2nd quarter. C WorldWide Group Holding A S now owns 702,069 shares of the biotechnology company’s stock valued at $13,051,000 after purchasing an additional 450,000 shares in the last quarter. Finally, FMR LLC raised its holdings in shares of Heron Therapeutics by 5.5% during the 1st quarter. FMR LLC now owns 8,473,847 shares of the biotechnology company’s stock valued at $207,101,000 after purchasing an additional 439,044 shares in the last quarter.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Read More: How to trade the most active stocks

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Citigroup Trims Mplx  Target Price to $32.00
Citigroup Trims Mplx Target Price to $32.00
Evofem Biosciences  Downgraded to Hold at Zacks Investment Research
Evofem Biosciences Downgraded to Hold at Zacks Investment Research
Zacks Investment Research Upgrades Cushman & Wakefield  to “Hold”
Zacks Investment Research Upgrades Cushman & Wakefield to “Hold”
Camtek  Upgraded to Hold at Zacks Investment Research
Camtek Upgraded to Hold at Zacks Investment Research
Atlassian  Upgraded at BidaskClub
Atlassian Upgraded at BidaskClub
S & T Bancorp  Raised to Hold at Zacks Investment Research
S & T Bancorp Raised to Hold at Zacks Investment Research


 
© 2006-2019 Zolmax.